Arinilda Campos Bragagnoli

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Kohei Shitara, Jaffer A. Ajani, Markus Moehler et al. · Nature · 2022 · 442 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

Markus Moehler, Mikhail Dvorkin, Narikazu Boku et al. · Journal of Clinical Oncology · 2020 · 223 citations · Full text

Medicine, Oncology, Pharmacology +15

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial

Yelena Y. Janjigian, Jaffer A. Ajani, Markus Moehler et al. · Journal of Clinical Oncology · 2024 · 216 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +1